RAS genes are mutated in approximately 30% of all human cancers. Interestingly, there exists a strong bias in favor of mutation of only one of the three major RAS genes in tumors of different cellular origins. NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease. To define the mechanism(s) responsible for this preference in melanocytes, we compared the transformation efficiencies of mutant NRAS and KRAS in immortal, non-transformed Ink4a/Arf-deficient melanocytes. NRAS mutation leads to increased cellular proliferation and is potently tumorigenic. In contrast, KRAS mutation does not enhance melanocyte proliferation and is only weakly tumorigenic on its own. Although both NRAS and KRAS activate mitogen-activated protein kinase signaling, only NRAS enhances MYC activity in these cells. Our data suggest that the activity of specific RAS isoforms is context-dependent and provide a possible explanation for the prevalence of NRAS mutations in melanoma. In addition, understanding this mechanism will have important implications for cancer therapies targeting RAS pathways.
Introduction
Molecular analysis of melanoma has identified specific genomic loci implicated in the genesis and progression of melanoma. A significant percentage of both familial and sporadic melanomas have mutations that functionally inactivate the tumor suppressor genes INK4a/ARF (Castellano and Parmiani, 1999) . Activated NRAS oncogenes, which activate mitogen-activated protein kinase (MAPK) signaling, have been detected in approximately 20% of human melanomas (Chin et al., 2006) . Moreover, expression of either an NRAS or HRAS oncogene in the melanocytes of Ink4a/Arfdeficient mice results in the formation of melanoma in 90 or 50% of the animals, respectively, by 6 months of age (Chin et al., 1997; Ackermann et al., 2005) . Recently, activating mutations in the BRAF gene, which also activates MAPK signaling, have been found in a high percentage (>65%) of melanomas (Davies et al., 2002) . With mutually exclusive mutations in RAS and BRAF, the MAPK signaling pathway is activated in over 85% of melanomas, indicating the importance of the RAS/MAPK pathway in melanomagenesis.
The RAS subfamily consists of Harvey(H)-RAS, neuroblastoma(N)-RAS, and two splice variants of Kirsten(K)-RAS (KRAS4A and KRAS4B). The RAS isoforms share a high degree of homology. The main differences between the isoforms are in the C-terminal hypervariable region, which contains the membrane targeting domain (Giehl, 2005) . HRAS and NRAS colocalize to lipid rafts, whereas KRAS is excluded from lipid rafts and localizes to the disordered plasma membrane (Prior and Hancock, 2001) . Differences in the hypervariable regions correlate with functional differences of the RAS isoforms in mammary epithelial cells (Kim et al., 2002) , whereas sequences between amino acids 84 and 143 are responsible for the greater transforming capabilities of HRAS in fibroblasts. Interestingly, NRAS shows greater activity in hemopoietic cells (Maher et al., 1995) . Moreover, while NRas and HRas are dispensable for mouse development both alone and in combination (Umanoff et al., 1995; Esteban et al., 2001) , mice that are completely devoid of KRas expression are embryonic lethal (Koera et al., 1997) . These data suggest that there are specific nonredundant functions of the RAS proteins in different cell types. However, the mechanism(s) underlying the biological differences between the RAS isoforms remain unclear.
In many tumors, oncogenic mutations have been identified at positions 12, 13 or 61, which cause RAS to remain constitutively active. With the exception of thyroid cancers, most tumors are associated with mutation of only one isoform of RAS and this association cannot be explained solely on differential regulation of RAS gene expression in different tissues (Kim et al., 2002) . Although approximately 20% of human melanomas have been found to harbor NRAS mutations, HRAS and KRAS mutations are rare (o1%) (Chin et al., 2006) . Interestingly, several reports have demonstrated that transformation of certain cells by specific RAS isoforms requires cooperation by a second oncogene such as MYC (Land et al., 1983; Sinn et al., 1987) . However, the mechanism responsible for this cooperation has not been elucidated in melanocytes.
Here, we report the isolation and characterization of a non-transformed, immortal Ink4a/Arf-deficient mouse melanocyte cell line, which was used to delineate the mechanism(s) responsible for the prevalence of NRAS mutations in melanocytes. We found that expression of mutant V12-NRAS increased the rate of proliferation of the melanocytes and was more potently transforming compared with melanocytes expressing V12-KRAS. The increased rate of proliferation was due to the ability of NRAS (but not KRAS) to prevent GSK-3-mediated phosphorylation of c-MYC. Furthermore, coexpression of c-MYC with KRAS in the melanocytes resulted in an increased rate of proliferation and transformation comparable to the rate of proliferation and transformation of V12-NRAS alone.
Results
Ink4a/Arf-deficient melanocytes are immortal in culture To study the role of different oncogenes in melanoma formation, we generated mouse melanocyte cell lines from Ink4a/Arf-deficient mice (Serrano et al., 1996) . We established a pure melanocyte culture (lab designation D6-MEL) and confirmed the melanocyte origin of the cells by immunohistochemical staining for tyrosinase expression (Aroca et al., 1993) (data not shown). It has been shown that Arf deficiency confers immortality on fibroblasts (Kamijo et al., 1997) , whereas Ink4a deficiency confers immortality on melanocytes (Sviderskaya et al., 2002) . Similarly, we observed that melanocytes isolated from Ink4a/Arf-deficient mice proliferated continuously and never experienced a detectable senescence crisis even after 30 population doublings, suggesting they are immortal in culture. To ensure that these cells were non-transformed, they were assayed for colony formation in soft agar as well as for tumor formation in nude mice. These cultures yielded no cells that were capable of anchorage-independent growth in soft agar and they were unable to produce tumors in nude mice (Table 1) , consistent with immortality but not transformation.
Previous studies have demonstrated that cell lines isolated from a common tissue tend to have consistent similarities in gene expression patterns (Scherf et al., 2000) . Therefore, to validate further the melanocyte origin of the D6-MEL cells and to justify the use of this cell line for studying melanomagenesis, we compared the gene expression profile of the D6-MEL cell line to the gene expression profiles of several other tissues and Ink4a/Arf-deficient cell lines (Figure 1) . In this analysis, the D6-MEL cell line clusters near another melanocyte cell line, Melan-A (Bennett et al., 1987) , indicating that these cells have similar patterns of gene expression. As such, these data suggest these cells were likely derived from a common tissue type. In contrast, D6-MEL and Melan-A have distinct gene expression patterns from Figure 1 Gene expression-based evaluation of the melanocytic origin of the D6-MEL cell line. RNA was isolated from the indicated cell lines and tissues and applied to in-house generated cDNA microarrays. Dendrograms reflective of the overall similarities and differences of the cell line and tissue gene expression patterns were generated from about 6000 of the best measured and variable features using average-linkage hierarchical clustering (see Materials and methods). In the dendrogram shown, a shorter arm indicates higher similarity, whereas a longer arm indicates lower similarity. All of the cell lines analysed are Ink4a/Arf-deficient. The samples used are as follows: VA-MEF, mouse embryonic fibroblasts; 3T3, NIH 3T3 fibroblasts; HRAS-MEL, melanoma cells isolated from an Ink4a/Arf-/-;tyrosinase-HRAS mouse; NRAS-MEL, D6-MEL melanocytes expressing V12-NRAS; VA-475, lymphoma cells isolated from Ink4a/Arf-deficient mice; Melan-A, a reported nontransformed melanocyte cell line; KRAS-MEL, D6-MEL melanocytes expressing V12-KRAS; D6-MEL, melanocytes isolated from an Ink4a/Arf-deficient mouse and established as a single cell clone; kidney, heart, lung and liver represent samples isolated from normal mouse tissue. 
RAS/MAPK activation induces anchorage-independent growth of melanocytes in vitro
The RAS/MAPK signaling pathway is activated in the vast majority of characterized malignant melanomas. Interestingly, NRAS mutations are common whereas KRAS and HRAS mutations are rarely detected in melanoma (Chin et al., 2006) . To determine the efficiency of melanocyte transformation by different isoforms of RAS, melanocytes were infected with retroviral vectors expressing either V12-NRAS or V12-KRAS. Although Q61R-NRAS is more common in melanoma and similar results were obtained with this mutant (data not shown), the V12 mutant was used in these studies such that a direct comparison could be made between the transforming capabilities of different RAS isoforms harboring the same mutation. Introduction of either V12-NRAS or V12-KRAS resulted in a significant increase in the total amount of RAS protein compared with uninfected melanocytes, as assessed using a pan-RAS antibody by Western blot (Figure 2a ). The ability of the mutant RAS isoforms to induce anchorage-independent growth of melanocytes was initially assayed in vitro by colony formation in soft agar. Whereas the parental, uninfected melanocytes were unable to grow in soft agar, melanocytes expressing activated V12-NRAS formed numerous colonies in soft agar, demonstrating that NRAS activation in melanocytes results in anchorage-independent growth, a characteristic of transformed cells. Although melanocytes expressing V12-KRAS formed colonies in soft agar, they were smaller and significantly fewer in number than melanocytes expressing V12-NRAS (Table 1) .
NRAS activation in melanocytes is potently tumorigenic in vivo Although anchorage-independent growth suggests that activated NRAS and KRAS are transforming in melanocytes, a more stringent assay of tumorigenic potential is the ability to form tumors in vivo. To determine the relative efficiency of tumor formation in vivo by different RAS isoforms, melanocytes expressing either V12-N, H or KRAS were injected subcutaneously into nude mice. Whereas the mice injected with the parental, uninfected melanocytes did not produce tumors, all of the mice injected with melanocytes expressing V12-NRAS developed tumors (Table 1, Figure 3 ). These tumors reached 200 mm 3 within 5 weeks. All of the mice injected with melanocytes expressing activated HRAS also developed tumors, but the growth of these tumors was slightly delayed compared with the NRAS tumors, taking an additional 2 weeks to reach 200 mm 3 . In contrast, only four of eight mice injected with melanocytes expressing activated KRAS developed tumors (Table 1, Figure 3 ), and these tumors progressed significantly more slowly than tumors expressing either activated NRAS or HRAS. The KRAS-expressing tumors reached a volume of 200 mm 3 5 weeks later than tumors expressing activated NRAS (Figure 3 ). The slightly slower tumor growth observed with melanocytes expressing V12-HRAS compared with melanocytes expressing V12-NRAS is most likely owing to differences in RAS expression levels between the virally infected NRAS cells and the cells from the Ink4a/Arf-null-Tyrosinase-HRAS mice, where expression of HRAS is driven from the tyrosinase promoter (Chin et al., 1997) . NRAS and KRAS expression was similar in the D6-MEL cells (Figure 2a) . Oncogenic potential of RAS isoforms in melanocytes T Whitwam et al NRAS and KRAS both activate the classical MAPK pathway in melanocytes In further support of the in vitro and in vivo growth differences between the N-, H-and KRAS-expressing melanocytes, these cell lines also have differences in their corresponding gene expression patterns (Figure 1 ). On the basis of gene expression data, the melanocytes expressing activated KRAS show a high degree of similarity to the D6-MEL and Melan-A cell lines. In contrast, the H-and NRAS-transformed melanocytes show lesser similarity to the D6-MEL and Melan-A melanocytes and have the greatest degree of similarity to the highly transformed and highly proliferative VA-475 lymphoma cells. These data suggest that the altered patterns of gene expression in the N-and KRASexpressing cell lines may be the result of differential activation of RAS signaling pathways and/or differences in overall cell proliferation.
To determine if the difference in in vivo tumorigenicity between KRAS and NRAS is due to differential activation of the classical MAPK signaling pathway (i.e., RAF/MEK/ERK; Figure 2b ), cell lysates were collected from D6-MEL cells expressing either V12-NRAS or V12-KRAS. Expression of either activated NRAS or KRAS strongly activated ERK in these cells ( Figure 2a) . As ERK phosphorylation mediated by both RAS isoforms is robust, the greater in vivo tumorigenic potential of NRAS appears not to be due to differential ERK activation.
NRAS, but not KRAS, increases the rate of proliferation of melanocytes and prevents GSK3-mediated phosphorylation of Myc In culturing the melanocytes expressing V12-NRAS or KRAS, we observed that cells expressing V12-NRAS grew at a faster rate than either uninfected melanocytes or melanocytes expressing V12-KRAS. This observation was confirmed by measurement of the in vitro proliferation rates of the cells. Expression of V12-NRAS significantly increased the proliferation rate of the melanocytes (Figure 4) . In contrast, the V12-KRAS melanocytes proliferated at the same rate as the uninfected melanocytes until day 8, at which point their growth was significantly reduced compared with that of all the other cell lines (Figure 4) . To determine the mechanism responsible for the disparity in growth and tumorigenicity, differences in downstream RAS effectors known to play a role in proliferation were evaluated.
The c-Myc protein plays a role in multiple cellular processes, including proliferation, and is a downstream target of RAS signaling (Sears, 2004) . We assessed endogenous c-Myc expression in cell lysates from uninfected melanocytes, and melanocytes expressing either V12-NRAS or V12-KRAS. When these samples were separated on a gradient polyacrylamide gel, a differential c-Myc banding pattern was observed. We suspected that the higher-molecular-weight bands were post-translationally modified forms of Myc, as Myc has been reported to be phosphorylated by ERK at serine 62 (S62) and by glycogen synthase kinase-3 (GSK3) at threonine 58 (T58) (Henriksson et al., 1993) . These two phosphorylation sites exert opposing control on c-Myc stability; whereas S62 phosphorylation stabilizes c-Myc, T58 phosphorylation promotes S62 dephosphorylation and ubiquitin-mediated proteasome degradation. Myc is normally turned over rapidly in cells, but RAS signaling stabilizes Myc by inducing phosphorylation of S62 through the MAPK/ERK pathway (Sears, 2004) and by inhibiting phosphorylation of Myc at T58 by GSK3 via phosphatidylinositol 3-kinase (PI3K) signaling (Gregory et al., 2003) (Figure 2b) . Consistent with observations in other cell types, the S62 singly phosphorylated protein was more pronounced in the NRAS-and KRAS-expressing melanocytes than in uninfected melanocytes (Figure 5a , 56-kDa band). However, whereas the uninfected melanocytes and the KRAS-expressing melanocytes both showed T58/S62 dual phosphorylation (Figure 5a , 51-kDa band), NRAS-expressing cells did not, suggesting that NRAS more effectively prevents GSK3-mediated phosphorylation of Myc at T58 than does KRAS in these cells.
To verify further the differential phosphorylation of Myc and to analyse the contribution of the PI3K/AKT/ GSK3 pathway to Myc regulation, uninfected melanocytes and melanocytes expressing either V12-NRAS or V12-KRAS were incubated in the presence or absence of lithium to inhibit GSK3-mediated phosphorylation of Myc at T58 (Klein and Melton, 1996; Kamemura et al., 2002) . Following treatment, endogenous Myc protein was immunoprecipitated and phosphorylation was detected using a T58 phospho-specific Myc antibody. Prominent T58 Myc bands were detected in lysates from uninfected melanocytes and melanocytes expressing V12-KRAS, but not from those expressing V12-NRAS (Figure 5b, top panel) . Upon inhibition of GSK3 activity by lithium treatment, T58 phosphorylation of Myc was no longer detectable ( Figure 5b, top panel) . Effective inhibition of GSK3 by lithium was verified by Figure 4 In vitro proliferation of melanocytes expressing different genes. Uninfected melanocytes (D6-MEL) or melanocytes infected with retroviruses containing V12-NRAS, V12-KRAS, MYC or V12-KRAS coexpressed with MYC were seeded in microtiter wells and assayed at the indicated time points. Viable cells were quantitated using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay by optical density readings at 490 nm (data are represented as mean7s.e.m.; n ¼ 3).
Oncogenic potential of RAS isoforms in melanocytes
T Whitwam et al analysis of the same cell lysates before immunoprecipitation of Myc using a phospho-specific GSK3 antibody (Figure 5b ). Inhibition of GSK3 correlates with an increase in the level of phosphorylated GSK3. These results suggest that phosphorylation of Myc at T58 is mediated by GSK3 in melanocytes, and further demonstrate that V12-NRAS effectively prevents GSK3-mediated phosphorylation of Myc whereas V12-KRAS does not.
Coexpression of KRAS and either MYC or AKT significantly increases the tumorigenicity of melanocytes
To determine if coexpression of KRAS with either AKT, MYC, or both AKT and MYC would result in tumorigenicity comparable to that induced by expression of NRAS alone, melanocytes expressing MYC or AKT were infected with retroviruses containing V12-KRAS to generate melanocytes expressing KRAS and MYC, KRAS and AKT, or KRAS, AKT and MYC. Melanocytes expressing AKT alone, MYC alone, and the combination of AKT and MYC in the absence of KRAS were generated as controls. Expression of individual genes was confirmed by Western blot (Figure 6 ). Expression of either MYC or AKT alone is not sufficient to transform the melanocytes even in the context of Ink4a/Arf deficiency. Neither soft agar colonies nor in vivo tumors formed from melanocytes expressing only MYC or AKT (Table 1, Figure 7) . However, coexpression of KRAS with either AKT or, more dramatically, MYC resulted in potent transformation. Whereas melanocytes expressing V12-KRAS alone only formed tumors in half of the injected mice with a long latency, tumors were detected in all of the mice injected with melanocytes coexpressing KRAS and AKT (Table 1 ). The kinetics of tumor growth outpaced that of KRAS-only tumors, but still lagged behind NRAS tumors (Figure 7) . Coexpression of KRAS and MYC was even more potently tumorigenic than KRAS with AKT. Tumors developed in all mice injected with KRAS-and MYC-expressing melanocytes (Table 1) ; the tumor growth kinetics were indistinguishable from the rate of NRAS-induced tumors. Additional expression of AKT did not significantly enhance the tumorigenicity of KRAS-and MYC-expressing melanocytes (Figure 7) . These results further support the idea that either MYC or AKT is capable of cooperating with KRAS in this system. Furthermore, in the absence of V12-KRAS expression, coexpression of MYC and AKT resulted in the formation of soft agar colonies but not (a) Cell lysates from uninfected melanocytes (À) or melanocytes infected with retroviruses containing V12-NRAS or V12-KRAS ( þ ) were collected in Myc lysis buffer, separated on a 4-20% polyacrylamide Tris-glycine gradient gel, and immunoblotted for endogenous Myc expression using an anti-Myc monoclonal antibody (9E10; a-MYC). The S62-Myc band (56 kDa) is predicted to be larger than the doubly phosphorylated S62/T58-Myc band (51 kDa) owing to glycosylation of T58 in the absence of phosphorylation (Kamemura et al., 2002) . The blot was re-probed for GAPDH to ensure equal loading (a-GAPDH). (b) Uninfected melanocytes (À) or melanocytes infected with retroviruses containing V12-NRAS (NRAS) or V12-KRAS (KRAS) were treated with either 20 mM LiCl or KCl (as a control) for 30 min. After treatment, cell lysates were collected in RIPA buffer and phosphorylated GSK3 (a-pGSK3) and tubulin (a-Tubulin) were detected from whole cell lysates, whereas T58 Myc phosphorylation (a-pT58) and total Myc (9E10; a-MYC) were detected from c-Myc immunoprecipitates with the antibodies indicated. Figure 7) . These results further illustrate the importance of a RAS signal in this context.
Proliferation rate of KRAS-expressing melanocytes is increased by MYC expression
To explore further the mechanisms that underlie the differences in tumorigenic potential of the RAS isoforms, and to characterize further how MYC coexpression increases the tumorigenicity of V12-KRAS melanocytes, the proliferation rates of melanocytes expressing V12-NRAS, V12-KRAS and MYC, as well as the combination of V12-KRAS and MYC, were measured. Although V12-KRAS or MYC expression alone did not affect the cellular proliferation rate, coexpression of MYC with V12-KRAS increased the proliferation rate of the melanocytes to a rate similar to that observed by V12-NRAS alone (Figure 4 ). This indicates that MYC expression cooperates with V12-KRAS by increasing the rate of cellular proliferation.
Discussion
Using a genetically defined system, we demonstrate that the combination of V12-NRAS expression and Ink4a/ Arf loss is potently tumorigenic in melanocytes, whereas transformation by V12-KRAS requires the expression of a cooperating oncogene. V12-NRAS expression alone significantly increases the proliferation of Ink4a/Arfdeficient melanocytes. In contrast, V12-KRAS expression does not enhance cell proliferation, but rather induces growth arrest at higher cell densities. Although tumors developed in half of the mice injected with V12-KRAS-expressing Ink4a/Arf-deficient melanocytes, the long latency and incomplete penetrance of tumor formation in these mice suggest that additional genetic changes were acquired over time.
It has been established that RAS and MYC can cooperate in the transformation of rodent fibroblast and mammary epithelial cells (Land et al., 1983; Sinn et al., 1987) . However, the mechanism responsible for this cooperation has not been elucidated in melanocytes. Analysis of downstream RAS effector pathways revealed that although both V12-NRAS and V12-KRAS efficiently activate the classical MAPK pathway in melanocytes, only V12-NRAS effectively prevents glycogen synthase kinase 3 (GSK3)-mediated phosphorylation of Myc via PI3K/AKT, which results in enhanced activity of endogenous Myc protein in these cells. These results are in agreement with observations in fibroblasts where HRAS more effectively activates PI3K than does KRAS (Yan et al., 1998) . As both HRAS and NRAS colocalize to lipid rafts, whereas KRAS is excluded from lipid rafts and localizes to the disordered plasma membrane (Prior and Hancock, 2001) , the more potent activation of PI3K/ AKT by NRAS and HRAS may be owing to differential membrane localization and therefore access to a defined subset of downstream effector proteins. Alternatively, recruitment of PI3K to distinct domains (e.g., lipid rafts) within the plasma membrane may result in activation that is more efficient than that of KRAS.
The importance of the PI3K/AKT/MYC pathway in melanoma genesis was further illustrated by the combination of V12-KRAS with either AKT or MYC, which results in transformation efficiencies similar to that of V12-NRAS alone. Inactivating phosphatase and tensin homolog deleted on chromosome ten (PTEN) mutations, which result in enhanced AKT activity, appear to be mutually exclusive with NRAS mutations in human melanoma tissues and cell lines, suggesting overlapping redundant functions. Furthermore, half of melanomas with BRAF mutations, which activate downstream MAPK signaling but not PI3K/AKT signaling, also harbor PTEN mutations (Goel et al., 2006) . Concurrent BRAF/PTEN mutations appear to function like an NRAS mutation in melanomagenesis.
Although we have observed that NRAS is the most potent RAS protooncogene in melanocytes, HRAS and KRAS mutations are clearly selected for in tumors of different cellular origins. The differences that we and others have observed in the ability of the RAS proteins to activate different effector molecules may explain the selection pressure for specific RAS mutations in certain human tumors. The presence of additional mutations in other genes most likely contributes to this selection pressure, and the multistep process of oncogenesis varies significantly between cell types. For example, in colorectal cancer loss of the adenomatous polyposis coli (APC) gene is an early event that results in increased levels of b-catenin and subsequent increases in MYC gene expression (Vogelstein et al., 1988) . As loss of APC typically precedes activation of KRAS in colorectal cancer progression, this may explain the selection pressure for KRAS mutation in those cells.
Our results demonstrate the importance of NRASmediated activation of both MAPK and PI3K/AKT/ MYC signaling in melanoma genesis and identify distinct differences between the signaling capabilities of NRAS and KRAS in melanocytes. These differences offer a rationale explanation for the greater occurrence of NRAS mutations relative to KRAS mutations in melanoma. In addition, the relative resistance to MEK inhibition of melanomas harboring NRAS mutations (Solit et al., 2006) suggests that these tumors may be ideal candidates for combination therapies that also target the PI3K/AKT/MYC pathway.
Materials and methods

Isolation of primary melanocytes and melanoma cells
Melanocytes were isolated from 3.5-day postnatal Ink4a/ Arf-null mice (Serrano et al., 1996) . Details of the isolation procedure and culture conditions are provided in Supplementary data. Mouse melanoma cells were established in culture from tumors that developed in Ink4a/Arf-/-;tyrosinase HRAS mice (Jackson Labs, Bar Harbor, ME, USA) (Chin et al., 1997) .
Microarray data generation and analysis Details of the microarray data generation are provided in Supplementary data. The gene expression data described in this paper have been deposited in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE6194 (Edgar et al., 2002) .
Vector constructs
Details of the RCASBP(M)-MYC, KRAS(G12V), AKT, NRAS(G12V) and NRAS(Q61R) cloning are provided in Supplementary data.
Virus propagation
Virus propagation was initiated by calcium phosphate transfection of plasmid DNA that contained the retroviral vector in proviral form as described previously (Holmen and Williams, 2005) .
Viral infections
Melanocytes were seeded in 6-well cluster dishes at a density of 5 Â 10 4 cells/well 16 h before infection. Viral infections were performed as described previously (Holmen and Williams, 2005) .
Cell lysis and immunoprecipitation
Infected melanocytes were lysed in either sodium dodecyl sulfate (SDS)-lysis buffer (50 mM Tris-HCl, pH 6.8, 100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue, 10% glycerol) or Myc lysis buffer (0.1% Triton-X-100 in phosphate-buffered saline) as indicated. Protein concentrations were determined using the Bio-Rad D C Protein Assay (Bio-Rad, Hercules, CA, USA). Immunoprecipitations are described in detail in Supplementary data. The samples were resolved on either 10, 14 or 4-20% Tris-glycine SDS polyacrylamide gels (Invitrogen, Carlsbad, CA, USA), transferred to nitrocellulose, and incubated for 1 h at room temperature in TBS-T (0.05% Tween-20 in Tris-buffered saline) blocking solution (5% non-fat dry milk).
Western blotting
Details of the antibodies used are provided in Supplementary data. Western blots were incubated in the primary antibody overnight at 41C, washed in TBS-T, and then incubated with either an anti-mouse or anti-rabbit IgG-horse radish peroxidase secondary antibody, as appropriate, diluted 1:2000 (Amersham, Piscataway, NJ, USA) for 1 h at room temperature. The blots were washed in TBS-T, incubated with ECL solutions as per the manufacturer's specifications (Amersham, Piscataway, NJ, USA), and exposed to film.
Growth in soft agar
To assess anchorage-independent growth, 1.5 Â 10 5 cells were suspended in 0.55% Difco agar noble (Becton Dickinson, Sparks, MD, USA) in MGM/10% fetal bovine serum (FBS) and layered over pre-solidified 0.65% Difco Noble Agar in MGM/10% FBS per well of a six-well dish. Each cell line was assayed in triplicate.
Cell proliferation studies Each cell line was seeded into 24 wells of a 96-well dish at a density of 5000 cells/well. The cells were cultured and assayed for proliferation in triplicate at the times indicated using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) according to the manufacturer's specifications.
In vivo studies Four-week-old female athymic nude mice were injected subcutaneously with 1 Â 10 7 cells/mouse in 100 ml Hanks' balanced salt solution. Tumor size was evaluated by caliper measurements, and tumor volume was calculated by length Â width Â depth. All experiments were performed in compliance with the guiding principles of the Guide for the Care and Use of Laboratory Animals (available at http:// www.nap.edu/books/0309053773/html/) and were approved by the VARI IACUC before experimentation.
